A phase I/II trial of radium-223 (Ra-223) in combination with pembrolizumab in patients (pts) with stage IV non-small cell lung cancer (NSCLC)
- Author
- M. Reck, K. F. Mileham, D. A. Clump, L. Decoster, A. Estival, E. Felip, P. Fried, L. Paz-Ares, M. Sebastian, N Vinolas Segarra, Veerle Surmont (UGent) , A. Wagner, S. M. Galdy and E. F. Smit
- Organization
Downloads
-
(...).pdf
- full text (Published version)
- |
- UGent only
- |
- |
- 84.87 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8680396
- MLA
- Reck, M., et al. “A Phase I/II Trial of Radium-223 (Ra-223) in Combination with Pembrolizumab in Patients (Pts) with Stage IV Non-Small Cell Lung Cancer (NSCLC).” ANNALS OF ONCOLOGY, vol. 31, no. Suppl 4, Elsevier, 2020, pp. S897–98, doi:10.1016/j.annonc.2020.08.1734.
- APA
- Reck, M., Mileham, K. F., Clump, D. A., Decoster, L., Estival, A., Felip, E., … Smit, E. F. (2020). A phase I/II trial of radium-223 (Ra-223) in combination with pembrolizumab in patients (pts) with stage IV non-small cell lung cancer (NSCLC). ANNALS OF ONCOLOGY, 31(Suppl 4), S897–S898. https://doi.org/10.1016/j.annonc.2020.08.1734
- Chicago author-date
- Reck, M., K. F. Mileham, D. A. Clump, L. Decoster, A. Estival, E. Felip, P. Fried, et al. 2020. “A Phase I/II Trial of Radium-223 (Ra-223) in Combination with Pembrolizumab in Patients (Pts) with Stage IV Non-Small Cell Lung Cancer (NSCLC).” In ANNALS OF ONCOLOGY, 31:S897–98. Amsterdam: Elsevier. https://doi.org/10.1016/j.annonc.2020.08.1734.
- Chicago author-date (all authors)
- Reck, M., K. F. Mileham, D. A. Clump, L. Decoster, A. Estival, E. Felip, P. Fried, L. Paz-Ares, M. Sebastian, N Vinolas Segarra, Veerle Surmont, A. Wagner, S. M. Galdy, and E. F. Smit. 2020. “A Phase I/II Trial of Radium-223 (Ra-223) in Combination with Pembrolizumab in Patients (Pts) with Stage IV Non-Small Cell Lung Cancer (NSCLC).” In ANNALS OF ONCOLOGY, 31:S897–S898. Amsterdam: Elsevier. doi:10.1016/j.annonc.2020.08.1734.
- Vancouver
- 1.Reck M, Mileham KF, Clump DA, Decoster L, Estival A, Felip E, et al. A phase I/II trial of radium-223 (Ra-223) in combination with pembrolizumab in patients (pts) with stage IV non-small cell lung cancer (NSCLC). In: ANNALS OF ONCOLOGY. Amsterdam: Elsevier; 2020. p. S897–8.
- IEEE
- [1]M. Reck et al., “A phase I/II trial of radium-223 (Ra-223) in combination with pembrolizumab in patients (pts) with stage IV non-small cell lung cancer (NSCLC),” in ANNALS OF ONCOLOGY, ELECTR NETWORK, 2020, vol. 31, no. Suppl 4, pp. S897–S898.
@inproceedings{8680396, articleno = {{Abstract: 1420TiP}}, author = {{Reck, M. and Mileham, K. F. and Clump, D. A. and Decoster, L. and Estival, A. and Felip, E. and Fried, P. and Paz-Ares, L. and Sebastian, M. and Vinolas Segarra, N and Surmont, Veerle and Wagner, A. and Galdy, S. M. and Smit, E. F.}}, booktitle = {{ANNALS OF ONCOLOGY}}, issn = {{0923-7534}}, language = {{eng}}, location = {{ELECTR NETWORK}}, number = {{Suppl 4}}, pages = {{Abstract: 1420TiP:S897--Abstract: 1420TiP:S898}}, publisher = {{Elsevier}}, title = {{A phase I/II trial of radium-223 (Ra-223) in combination with pembrolizumab in patients (pts) with stage IV non-small cell lung cancer (NSCLC)}}, url = {{http://doi.org/10.1016/j.annonc.2020.08.1734}}, volume = {{31}}, year = {{2020}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: